News - Pharmaphorum

Latest News

in News News
Orchard raises $150m to develop gene therapies
August 14, 2018 Share
X
Orchard raises $150m to develop gene therapies
https://pharmaphorum.com/news/orchard-raises-150m-to-develop-gene-therapies/
in News News
Samsung Bioepis and Takeda begin first trial from R&D tie-up
August 13, 2018 Share
X
Samsung Bioepis and Takeda begin first trial from R&D tie-up
https://pharmaphorum.com/news/samsung-bioepis-and-takeda-begin-first-trial-from-rd-tie-up/

Sarepta dives deeper into gene therapy

Sarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a

Sarepta dives deeper into gene therapy

https://pharmaphorum.com/news/sarepta-dives-deeper-gene-therapy/

Spark shares tank after haemophilia gene therapy safety signal

Biotech still pressing on with late stage trials

Spark shares tank after haemophilia gene therapy safety signal

https://pharmaphorum.com/news/spark-shares-tank-after-haemophilia-gene-therapy-safety-signal/

Lundbeck brings third Parkinson’s drug into clinic

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody

Lundbeck brings third Parkinson’s drug into clinic

https://pharmaphorum.com/news/lundbeck-brings-third-parkinsons-drug-into-clinic/

See all

More news

Antares to develop injector pen drug with Pfizer

New Jersey based Antares has signed a deal with pharma giant Pfizer to develop an auto injector pen

Antares to develop injector pen drug with Pfizer

https://pharmaphorum.com/news/antares-to-develop-injector-pen-drug-with-pfizer/

Boehringer joins UK academics in battle against cystic fibrosis

Boehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium announced a global collaboration to develop a

Boehringer joins UK academics in battle against cystic fibrosis

https://pharmaphorum.com/news/boehringer-battles-against-cystic-fibrosis/

Neurofibromatosis treatment granted orphan status by EMA

AstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped

Neurofibromatosis treatment granted orphan status by EMA

https://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/

New Huntington’s drug granted priority designation

Roche’s treatment for Huntington’s disease has received a priority designation by the European regulator, sparking hope that a

New Huntington’s drug granted priority designation

https://pharmaphorum.com/news/huntingtons-drug-granted-priority-designation/

Abbott upgrades brain implant software

The US Food and Drug Administration has approved an over-the-air software upgrade for Infinity implants manufactured by Abbott,

Abbott upgrades brain implant software

https://pharmaphorum.com/news/abbott-upgrades-brain-implants-software/

New tuberculosis drug could help eradicate global killer

A groundbreaking drug, rifampin, could help to end the global tuberculosis epidemic, according to researchers. Clinical trials carried

New tuberculosis drug could help eradicate global killer

https://pharmaphorum.com/news/new-tuberculosis-drug-could-help-eradicate-global-killer/

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that

FDA grants leukaemia drug ‘breakthrough’ status

https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/

The first lipodystrophy treatment for European patients

Novelion Therapeutics’ Myalepta (metreleptin) developed for the ultra-rare condition lipodystrophy has been approved by the European Commission, giving

The first lipodystrophy treatment for European patients

https://pharmaphorum.com/news/the-first-lipodystrophy-treatment-for-european-patients/

Shionogi’s Mulpleta gets FDA green light for patients with liver disease

The US drug regulator has approved Mulpleta (lusutrombopag) as a treatment for thrombocytopenia in certain patients with chronic

Shionogi’s Mulpleta gets FDA green light for patients with liver disease

https://pharmaphorum.com/news/shionogis-mulpleta-gets-fda-green-light-for-patients-with-liver-disease/

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

https://pharmaphorum.com/news/roche-ms-ocrevus-blockbuster/

Merck & Co’s Keytruda shows potential in head and neck cancer use

Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head

Merck & Co’s Keytruda shows potential in head and neck cancer use

https://pharmaphorum.com/news/keytruda-shows-promise-first-line-skin-cancer-treatment/

GSK’s Nucala unlikely to get COPD use after panel vote

FDA due to make decision in September

GSK’s Nucala unlikely to get COPD use after panel vote

https://pharmaphorum.com/news/gsks-nucala-unlikely-to-get-copd-use-after-panel-vote/

GSK signs $300m R&D deal with 23andMe

GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to

GSK signs $300m R&D deal with 23andMe

https://pharmaphorum.com/r-d/gsk-welcomes-23andmes-dna-database/

Biogen and Eisai Alzheimer’s drug excites doctors, but not investors

Investors spooked after string of failures

Biogen and Eisai Alzheimer’s drug excites doctors, but not investors

https://pharmaphorum.com/news/biogen-and-eisai-alzheimers-drug-excites-doctors-but-not-investors/

PureTech to research Alzheimer’s drugs based on ‘brain drain’ theory

US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases

PureTech to research Alzheimer’s drugs based on ‘brain drain’ theory

https://pharmaphorum.com/news/puretech-research-alzheimers-brain-drain-theory/

Search

Advanced Search

Trending

Latest News

More news